A pox on Hox
20 July, 2006 by External Press Release AuthorHox genes - long thought to define the body plans of all animals - are not used by corals.
BioDiem revenue up, loss under $100,000
01 March, 2006 by Ruth BeranMilestone payments from partner Nobilon led to Melbourne's BioDiem (ASX:BDM) posting strong results for the half year ending December 31, 2005 with revenue up 88 per cent to $2.9 million and a loss of only $96,000 compared with the previous corresponding half.
Peacock appointed Australia's chief scientist
01 March, 2006 by Graeme O'NeillPioneering CSIRO plant molecular geneticist Dr Jim Peacock, has been appointed Australia's chief scientist, in the wake of the resignation of Dr Robin Batterham after six years in the job.
Past five years show life sciences industry growth
01 March, 2006 by Ruth BeranThe Australian life sciences industry has grown significantly in the past five years and shows signs of a positive future, according to the 15th edition of PricewaterhouseCoopers' quarterly BioForum report.
Bavarian Nordic looking for strategic partner, says company chairman
01 March, 2006 by Staff WritersDenmark's Bavarian Nordic is actively seeking to be part of the consolidation process now underway in the international vaccine industry, and would not turn down a takeover offer if the price were right, company chairman Asgar Aamund said on Tuesday.
Student entrepreneurs scoop award pool
28 February, 2006 by Ruth BeranA team of 12 students from the Bio21 and Howard Florey Institutes scooped the pool at an awards ceremony held last week in Melbourne for the 2005 Young Achievers Australia Biotechnology Entrepreneur program.
BIO delegates brush up on negotiation skills
28 February, 2006 by Ruth BeranIn the lead up to the BIO Conference 2006, delegates are being invited to attend Bootcamp, a series of full-day workshops being held around Australia on negotiating technology deals.
Biotechs ape pharma strategy as profits grow
28 February, 2006 by Staff WritersAs the biotechnology industry matures and more companies become profitable, many are looking outside their traditional business areas to grow -- with mixed results.
Novogen's revenues down, loss up
27 February, 2006 by Ruth BeranCancer drug developer Novogen's (ASX:NRT, Nasdaq:NVGN) revenue was down 10 per cent for the half year to December 31, 2005 compared with the previous corresponding period, due to a decrease in sales of its over-the-counter (OTC) natural products for menopause following a resurgence in rival prescribed drugs.
P&G exec tips industrial biotech will dominate
27 February, 2006 by Iain ScottIndustrial biotech will eclipse its so-called 'red' and 'green' cousins, as industries are forced to adapt to environmental pressure, the head of global biosciences at the giant Proctor & Gamble corporation has predicted.
GTG forms alliance with US MetaMorphix
27 February, 2006 by Helen SchullerMelbourne's Genetic Technologies (ASX:GTX, Nasdaq:GENE) has formed a strategic alliance with MetaMorphix, a developer of new genetic markers.
In brief: GTG, Life Therapeutics, AusBiotech, CyGenics
21 February, 2006 by Ruth BeranGenetic Technologies (ASX:GTG; Nasdaq:GENE) has appointed London-based lawyer SJ Berwin to help the company expand its licensing program for its non-coding patents in the UK and in Europe
CSIRO signs research agreement with Chinese Ministry of Science
16 February, 2006 by Helen SchullerThe CSIRO and the Chinese Government have signed an agreement designed to strengthen the relationship between research laboratories in Australia and China.
Panbio subsidiary wins US defence department grant
16 February, 2006 by Ruth BeranPanbio's (ASX:PBO) US subsidiary Panbio Inc has been awarded almost US$100,000 (AUD$135,000) in funding from the US Deparment of Defence.
NSW, China sign tech park agreement
14 February, 2006 by Helen SchullerThe NSW and Chinese governments have signed an agreement to help foster collaborative relationships between science and technology parks and commercial enterprises.
